Peter H F Hobbelen1, Julia Stowe2, Gayatri Amirthalingam2, Liz Miller2, Albert-Jan van Hoek3. 1. Immunisation, Hepatitis and Blood Safety Department, Public Health England, 61 Colindale Avenue, NW9 5EQ, London, UK. Electronic address: peter.hobbelen@phe.gov.uk. 2. Immunisation, Hepatitis and Blood Safety Department, Public Health England, 61 Colindale Avenue, NW9 5EQ, London, UK. 3. Immunisation, Hepatitis and Blood Safety Department, Public Health England, 61 Colindale Avenue, NW9 5EQ, London, UK; Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, Keppel Street, WC1E 7HT, London, UK.
Abstract
OBJECTIVES: We aimed to determine the hospital burden of varicella-zoster virus infection (VZV) in England during 2004-2013 to support a future cost-effectiveness analysis of a childhood varicella vaccination programme. METHODS: We analysed the incidence, duration, outcome and costs of hospitalisations for VZV using the Hospital Episode Statistics (HES) database for the general and immunocompetent population. Mortality in HES was validated using data from the Office for National Statistics (ONS). RESULTS: The average annual incidences of admissions due to varicella and herpes zoster were 7.6 (7.3-7.9) and 8.8 (8.6-9.0) per 100,000, respectively. The immunocompetent population accounted for 93% and 82% of the admissions due to varicella and herpes zoster, respectively. The average yearly number of hospital days was 10,748 (10,227-11,234) for varicella and 41,780 (40,257-43,287) for herpes zoster. The average yearly hospital costs (£2013/14) were £6.8 million (6.4-7.2) for varicella and £13.0 million (12.8-13.4) for herpes zoster. The average annual numbers of deaths identified in HES due to varicella and herpes zoster were 18.5 (14.3-22.8) and 160 (147-172), respectively. Comparison with ONS mortality data indicated a high level of uncertainty. CONCLUSIONS: Most of the hospital burden due to VZV-virus in England occurs in the immunocompetent population and is potentially vaccine-preventable. Crown
OBJECTIVES: We aimed to determine the hospital burden of varicella-zoster virus infection (VZV) in England during 2004-2013 to support a future cost-effectiveness analysis of a childhood varicella vaccination programme. METHODS: We analysed the incidence, duration, outcome and costs of hospitalisations for VZV using the Hospital Episode Statistics (HES) database for the general and immunocompetent population. Mortality in HES was validated using data from the Office for National Statistics (ONS). RESULTS: The average annual incidences of admissions due to varicella and herpes zoster were 7.6 (7.3-7.9) and 8.8 (8.6-9.0) per 100,000, respectively. The immunocompetent population accounted for 93% and 82% of the admissions due to varicella and herpes zoster, respectively. The average yearly number of hospital days was 10,748 (10,227-11,234) for varicella and 41,780 (40,257-43,287) for herpes zoster. The average yearly hospital costs (£2013/14) were £6.8 million (6.4-7.2) for varicella and £13.0 million (12.8-13.4) for herpes zoster. The average annual numbers of deaths identified in HES due to varicella and herpes zoster were 18.5 (14.3-22.8) and 160 (147-172), respectively. Comparison with ONS mortality data indicated a high level of uncertainty. CONCLUSIONS: Most of the hospital burden due to VZV-virus in England occurs in the immunocompetent population and is potentially vaccine-preventable. Crown
Authors: Peter Wutzler; Paolo Bonanni; Margaret Burgess; Anne Gershon; Marco Aurélio Sáfadi; Giacomo Casabona Journal: Expert Rev Vaccines Date: 2017-07-13 Impact factor: 5.217
Authors: Nikki M Turner; Jayden MacRae; Mary L Nowlan; Lynn McBain; Maria H Stubbe; Anthony Dowell Journal: BMJ Open Date: 2018-05-31 Impact factor: 2.692
Authors: Nick Andrews; Julia Stowe; Galena Kuyumdzhieva; Bersabeh Sile; Ivelina Yonova; Simon de Lusignan; Mary Ramsay; Gayatri Amirthalingam Journal: BMJ Open Date: 2020-07-07 Impact factor: 2.692
Authors: Pieter T de Boer; Alies van Lier; Hester de Melker; Albert J M van Wijck; Jan C Wilschut; Albert Jan van Hoek; Maarten J Postma Journal: BMC Med Date: 2018-12-06 Impact factor: 8.775